Fennec Pharmaceuticals Inc.

5.57-0.0200-0.36%Vol 20.49K1Y Perf -23.32%
Jun 24th, 2022 16:00 DELAYED
BID4.34 ASK5.75
Open5.65 Previous Close5.59
Pre-Market- After-Market-
 - -  - -%
Target Price
9.33 
Analyst Rating
Moderate Buy 1.67
Potential %
67.50 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.44
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
27.94 
Earnings Rating
Strong Buy
Market Cap145.04M 
Earnings Date
9th Aug 2022
Alpha0.02 Standard Deviation0.18
Beta-0.07 

Today's Price Range

5.515.70

52W Range

3.8210.08

5 Year PE Ratio Range

-12.20-13.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.27%
1 Month
-0.71%
3 Months
-6.07%
6 Months
24.05%
1 Year
-23.32%
3 Years
43.56%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FENC5.57-0.0200-0.36
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
8.50
9.00
0.26
0.40
-89.60
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-9 571.20
-9 566.50
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.13-0.14-7.69
Q04 20213.52-0.18-105.11
Q03 2021-0.18-0.1611.11
Q02 2021-0.19-0.1521.05
Q01 2021-0.12-0.18-50.00
Q04 2020-0.19-0.1331.58
Q03 2020-0.18-0.24-33.33
Q02 2020-0.19-0.21-10.53
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.146.67Positive
9/2022 QR-0.1016.67Positive
12/2022 FY-0.4516.67Positive
12/2023 FY-0.23-675.00Negative
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.14
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume20.49K
Shares Outstanding26.04K
Shares Float17.60M
Trades Count129
Dollar Volume114.78K
Avg. Volume23.29K
Avg. Weekly Volume19.36K
Avg. Monthly Volume21.31K
Avg. Quarterly Volume29.22K

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) stock closed at 5.57 per share at the end of the most recent trading day (a -0.36% change compared to the prior day closing price) with a volume of 20.49K shares and market capitalization of 145.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Fennec Pharmaceuticals Inc. CEO is Rostislav Raykov.

The one-year performance of Fennec Pharmaceuticals Inc. stock is -23.32%, while year-to-date (YTD) performance is 26.59%. FENC stock has a five-year performance of %. Its 52-week range is between 3.8219 and 10.0781, which gives FENC stock a 52-week price range ratio of 27.94%

Fennec Pharmaceuticals Inc. currently has a PE ratio of -9.30, a price-to-book (PB) ratio of 11.71, a price-to-sale (PS) ratio of 660.88, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.44%, a ROC of -68.20% and a ROE of -87.08%. The company’s profit margin is -%, its EBITDA margin is -9 566.50%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Fennec Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Fennec Pharmaceuticals Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Fennec Pharmaceuticals Inc. is Moderate Buy (1.67), with a target price of $9.33, which is +67.50% compared to the current price. The earnings rating for Fennec Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fennec Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fennec Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.38, ATR14 : 0.29, CCI20 : -22.18, Chaikin Money Flow : -0.13, MACD : -0.06, Money Flow Index : 54.69, ROC : -1.99, RSI : 47.75, STOCH (14,3) : 48.03, STOCH RSI : 0.93, UO : 36.51, Williams %R : -51.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fennec Pharmaceuticals Inc. in the last 12-months were: Chris A. Rallis (Option Excercise at a value of $14 999)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.50

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

CEO: Rostislav Raykov

Telephone: +1 919 636-4530

Address: 68 TW Alexander Drive, Research Triangle Park 27709, NC, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

52%48%

Bearish Bullish

66%34%

TipRanks News for FENC

Tue, 01 Mar 2022 16:25 GMT Fennec Pharmaceuticals (FENC) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits